Discounted Cash Flow Rating

Neutral

Return on Equity Rating

Strong Sell

Debt to Equity Rating

Neutral

Price to Earnings Rating

Strong Sell

Analyst Rating

Sell

Simple Moving Average

Sell

Exponential Moving Average

Sell

Relative Strength Index

Buy

Standard Deviation

Strong Buy

Williams %R

Strong Buy

Average Directional Index

Sell

Insider Trading

Strong Buy

Wall Street Data Solutions Rating

Neutral

B

Verve Therapeutics, Inc. Common Stock (VERV)

Pharmaceutical Preparations

https://www.vervetx.com

Verve Therapeutics Inc is a genetic medicines company pioneering a new approach to the care of cardiovascular disease, transforming treatment from chronic management to single-course gene editing medicines. The company's initial two programs target PCSK9 and ANGPTL3, genes that have been extensively validated as targets for lowering blood lipids such as low-density lipoprotein cholesterol, a root cause of cardiovascular disease. The company views its operations as and manages its business in one operating segment operating exclusively in the United States.

201 BROOKLINE AVENUE, SUITE 601
BOSTON, MA

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

06/17/2021

Market Cap

378,694,637

Shares Outstanding

76,250,000

Weighted SO

80,424,065

Total Employees

N/A

Upcoming Earnings

08/08/2024

Similar Tickers

ADPT --.--%

BEAM --.--%

CRBU --.--%

SANA --.--%

NTLA --.--%

EDIT --.--%

CRSP --.--%

PRME --.--%

THRX --.--%

Beta

1.8500

Last Div

0.0000

Range

4.305-20.12

Chg

-0.0650

Avg Vol

1377785

Mkt Cap

378694637

Exch

NASDAQ

Country

US

Phone

617 603 0070

DCF Diff

3.2865

DCF

1.2135

Div Yield

0.0000

P/S

18.3405

EV Multiple

-1.4261

P/FV

0.6902

Div Yield %

0.0000

P/E

-1.9565

PEG

-0.0783

Payout

0.0000

Current Ratio

14.6379

Quick Ratio

14.6379

Cash Ratio

3.5051

DSO

53.7389

DIO

0.0000

Op Cycle

53.7389

DPO

311.1722

CCC

-257.4333

Gross Margin

0.6118

Op Margin

-10.7500

Pretax Margin

-9.3171

Net Margin

-9.3302

Eff Tax Rate

-0.0007

ROA

-0.2749

ROE

-0.3520

ROCE

-0.3360

NI/EBT

1.0014

EBT/EBIT

0.8667

EBIT/Rev

-10.7500

Debt Ratio

0.1034

D/E

0.1327

LT Debt/Cap

0.1022

Total Debt/Cap

0.1172

Int Coverage

-35.3222

CF/Debt

-1.7900

Equity Multi

1.2835

Rec Turnover

6.7921

Pay Turnover

1.1730

Inv Turnover

0.0000

FA Turnover

0.2026

Asset Turnover

0.0295

OCF/Share

-1.5403

FCF/Share

-1.5956

Cash/Share

6.8381

OCF/Sales

-6.2830

FCF/OCF

1.0359

CF Coverage

-1.7900

ST Coverage

-12.6038

CapEx Coverage

-27.8452

Div&CapEx Cov

-27.8452

P/BV

0.6902

P/B

0.6902

P/S

18.3405

P/E

-1.9565

P/FCF

-2.8179

P/OCF

-2.9053

P/CF

-2.9053

PEG

-0.0783

P/S

18.3405

EV Multiple

-1.4261

P/FV

0.6902

DPS

0.0000

Latest Headlines (EST)

The Motley Fool Apr 18, 22:36 Why Verve Therapeutics Zoomed 40% Higher This Week GlobeNewswire Inc. Oct 25, 00:43 VERV DEADLINE NOTICE: ROSEN, A LONGSTANDING LAW FIRM, Encourages Verve Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important October 28 Deadline in Securities Class Action Commenced by the Firm – VERV GlobeNewswire Inc. Oct 24, 00:19 Verve Therapeutics, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. October 28, 2024 Deadline to file Lead Plaintiff Motion GlobeNewswire Inc. Oct 23, 00:11 VERV FINAL DEADLINE: RLF, RECOGNIZED INVESTOR COUNSEL, Encourages Verve Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important October 28 Deadline in Securities Class Action Commenced by the Firm – VERV GlobeNewswire Inc. Oct 19, 15:57 VERV DEADLINE: RLF, THE FIRST FILING FIRM, Encourages Verve Therapeutics, Inc. Investors With Losses in Excess of 100K to Secure Counsel Before Important October 28 Deadline in Securities Class Action Commenced by the Firm – VERV GlobeNewswire Inc. Oct 18, 00:35 Pixalate Releases Q2 2024 APAC Supply-Side Platform (SSP) Market Share Rankings for Mobile Apps & Web: Google AdExchange No. 1 on Web in China (48%) and Japan (46%) GlobeNewswire Inc. Oct 11, 23:45 ROSEN, A LEADING LAW FIRM, Encourages Verve Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action Commenced by the Firm – VERV GlobeNewswire Inc. Sep 28, 13:56 ROSEN, A LEADING NATIONAL FIRM, Encourages Verve Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – VERV GlobeNewswire Inc. Sep 22, 01:00 Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against WEBTOON, Verve, and Ardelyx and Encourages Investors to Contact the Firm GlobeNewswire Inc. Sep 21, 19:19 ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Verve Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – VERV GlobeNewswire Inc. Sep 17, 22:31 VERV CLASS ACTION: Verve Therapeutics, Inc. Stockholders Should Contact Robbins LLP for Information About the Securities Class Action Lawsuit GlobeNewswire Inc. Sep 15, 20:00 VERV SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Verve Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! GlobeNewswire Inc. Sep 13, 21:11 ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Verve Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – VERV GlobeNewswire Inc. Sep 10, 01:00 Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against WEBTOON, Verve, and Ardelyx and Encourages Investors to Contact the Firm GlobeNewswire Inc. Sep 01, 18:56 ????, ????? ????? ??? ??????? ???????, ?????? ?? ?????? Verve Therapeutics, Inc ???? ????? ???? ????? ??? ???? ?????? ??????? ??????? ??? ?????? ??????? ?? ??? ????? – VERV GlobeNewswire Inc. Sep 01, 17:25 ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Verve Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – VERV Investing.com Jan 16, 05:22 Dow Jones Extends Historic Streak: Are More All-Time Highs in the Cards? GlobeNewswire Inc. Jan 02, 06:30 Verve Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference The Motley Fool Dec 31, 08:45 2 Gene-Editing Stocks That Might Be the Next CRISPR Therapeutics The Motley Fool Dec 31, 08:45 2 Gene-Editing Stocks That Might Be the Next CRISPR Therapeutics

Revenue Product Segmentation